Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11002083 | 0.86 | GLS (0.67) | RECQLP2RX4GLSKMT2AMEN1 | |
| SCHEMBL1728790 | 0.83 | GLS (0.64) | RECQLGLSALDH1A1MAPTCFTR | |
| SCHEMBL20775125 | 0.83 | RECQL (0.57) | RECQLGLSCFTRACHECNR2 | |
| SCHEMBL30346162 | 0.80 | RECQL (1.00) | RECQLKMT2AMEN1ALDH1A1KMO | |
| SCHEMBL248214 | 0.80 | RECQL (1.00) | RECQLKMT2AMEN1ALDH1A1KMO | |
| SCHEMBL531900 | 0.79 | RECQL (0.52) | RECQLKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5430669 | 0.79 | RECQL (0.84) | RECQLKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5435879 | 0.79 | GLS (0.61) | RECQLGLSKMT2AACHECNR2 | |
| SCHEMBL1135534 | 0.79 | RECQL (0.77) | RECQLKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL8156564 | 0.77 | GLS (0.56) | RECQLGLSADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103958466-A | Nitrogen-containing heterocyclic compounds as CRTH2 antagonists | KBP BIOSCIENCES CO LTD | 2014-07-30 | — | — | CN | disclosed |
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | RECQL 2113/4885P2RX4 1224/4885GLS 2693/4885 |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | RECQL 524/4885P2RX4 1279/4885GLS 3154/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | RECQL 2113/4885P2RX4 1224/4885GLS 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.